CEO/Co-founder
Precision Neuroscience
Precision Neuroscience develops a fully implantable brain-computer interface designed to restore digital communication and device control for people with paralysis and other severe neurological conditions. Its Layer 7 Cortical Interface uses a non-penetrating, thin-film electrode array that rests on the brain's surface, capturing high-resolution neural signals without harming tissue. The system has received FDA clearance and has been implanted in more than 50 patients across multiple leading hospital partners.
- Medical Devices
- Healthcare Technology
- Hardware
- Artificial Intelligence
- Biotechnology
Updated 6 days ago
Funding
Raised to date
$430MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 4 rounds
+14$250M · Series D
Announced Sep 2026
Disclosed cumulative: $405M
4/4
RoundDateAmountValuationInvestors
Founders
Product
Problem
Individuals with paralysis and other severe neurological conditions often lose the ability to communicate and interact with digital devices, creating profound barriers to independence and quality of life. Existing brain-computer interfaces (BCIs) frequently require penetrating electrodes, which carry safety risks and limit scalability for broad clinical adoption.
Solution
Precision Neuroscience is building a fully implantable BCI that creates a high-bandwidth digital connection with the brain without harming neural tissue. The system uses a thin-film electrode array that rests on the brain's surface to capture detailed electrical signals, which are then processed by an implanted unit and translated into digital commands. This enables users to operate computers, communicate, and control external devices using thought alone. The non-penetrating design is intended to be safer and more scalable than traditional approaches, supporting broader deployment across clinical settings. The company has demonstrated high-accuracy sensory and motor decoding as well as focal electrical stimulation in animal studies, and has implanted its device in more than 50 human patients during standard neurosurgical procedures.
Target Audience
Primary users are individuals living with paralysis, spinal cord injury, ALS, and other neurological conditions, as well as clinical researchers and hospital systems seeking advanced BCI technology for restorative treatments.
Features
- Layer 7 Cortical Interface with FDA clearance, featuring a non-penetrating, thin-film electrode array for high-resolution neural recording
- Fully implantable system with a processing unit placed between the skull and scalp, eliminating external hardware
- High-bandwidth signal processing capable of translating complex neural patterns into real-time digital commands
- Each postage stamp-sized module contains 1,024 electrodes; up to four modules can cover approximately 8 cm² of cortex with more than 4,000 electrodes
- Minimally invasive and safely removable design intended to reduce surgical risk and support scalable clinical use
- Active clinical studies with implanted patients across multiple leading hospital partners, including Mount Sinai, Penn Medicine, and Mass General Brigham